Lung cancer is the leading cause of cancer death in the United States. Small cell lung carcinoma is the most aggressive type of lung cancer and is responsible for the high mortality. Because of the size and distribution of small lung cancer, cytoreductive surgery is not very effective for this disease and therefore chemotherapy and/or radiation are the treatment of choice. However, the efficacy of chemotherapy in lung cancer is limited by the fast development of cancer cell resistance during the treatment. Development of resistance demands significant increases in the doses of the toxic anticancer drug, thus producing adverse side effects upon healthy organs. Two main mechanisms are responsible for the observed resistance: pump and nonpump resistance. Pump resistance is caused by membrane efflux pumps that decrease the anticancer drug concentration inside the cells. The main transporters responsible for the pump resistance in lung cancer cells are the members of the so-called """"""""multidrug resistance associated proteins"""""""" (MRP). P-glycoprotein efflux pump does not play an important role in lung cancer resistance. Nonpump drug resistance is primarily attributed to the activation of antiapoptotic cellular defense and BCL2 protein is a key player in this defense. The main objective of the proposed research is to mitigate the above described resistance through the development, manufacture, characterization and in vitro and in vivo evaluation of a novel drug delivery system which contains four main components: (1) liposomes as a carrier;(2) anticancer drug (doxorubicin);(3) suppressor of pump drug resistance (antisense oligonucleotides or siRNA targeted to MRP1 and MRP2 proteins);(4) suppressor of nonpump cellular resistance (antisense oligonucleotides or siRNA targeted to the BCL2 protein). In addition to the simultaneous suppression of pump and nonpump cellular resistance the use of proposed liposomal drug delivery system allows for inhalatory local delivery of active components directly to the lungs minimizing adverse side effects. We hypothesize that simultaneous suppression of pump and nonpump cellular resistance will significantly increase the efficacyof chemotherapy of resistant lung cancer. The proposed drug delivery system utilizes a novel two-pronged molecular targeting strategy (simultaneous targeting of proteins that are key players in cellular pump and nonpump resistance). This will permit us to increase the efficacyof cancer chemotherapy by simultaneous suppression of pump and nonpump resistance.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Fu, Yali
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rutgers University
Schools of Pharmacy
New Brunswick
United States
Zip Code
Kuzmov, Andriy; Minko, Tamara (2015) Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 219:500-18
Garbuzenko, Olga B; Winkler, Jennifer; Tomassone, M Silvina et al. (2014) Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs. Langmuir 30:12941-9
Garbuzenko, Olga B; Mainelis, Gediminas; Taratula, Oleh et al. (2014) Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med 11:44-55
Savla, Ronak; Garbuzenko, Olga B; Chen, Suzie et al. (2014) Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy. Pharm Res 31:3487-502
Mainelis, G; Seshadri, S; Garbuzenko, O B et al. (2013) Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J Aerosol Med Pulm Drug Deliv 26:345-54
Shah, Vatsal; Taratula, Oleh; Garbuzenko, Olga B et al. (2013) Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr Drug Discov Technol 10:8-15
Ivanova, Vera; Garbuzenko, Olga B; Reuhl, Kenneth R et al. (2013) Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm 84:335-44
Taratula, Oleh; Kuzmov, Andriy; Shah, Milin et al. (2013) Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 171:349-57
Savla, Ronak; Minko, Tamara (2013) Nanotechnology approaches for inhalation treatment of fibrosis. J Drug Target 21:914-25
Taratula, Oleh; Garbuzenko, Olga B; Chen, Alex M et al. (2011) Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 19:900-14

Showing the most recent 10 out of 28 publications